Ublituximab Completed Phase 3 Trials for Chronic Lymphocytic Leukemia Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) |